Nontuberculous Mycobacterial Pulmonary Disease Indication Strategy Report 2026: CFTR, Trials and Whitespace uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Neurimmune 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Tuberculosis Indication Strategy Report 2026: TLR2, Trials and Deals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Humabs BioMed 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

COVID-19 Indication Strategy Report 2026: ACE2, Trials and Deals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Influenza Indication Strategy Report 2026: IFITM3, Trials and Deals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Spexis 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Respiratory Syncytial Virus Infection Indication Strategy Report 2026: CX3CR1, Trials and Deals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Anaveon 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Araris Biotech 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Memo Therapeutics 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Oculis 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.